tbuckley/cabot-search huggingface dataset:
FRI0601 The nature and extent of data items collected across european pregnancy registers – first results of the european network of pregnancy registers in rheumatology (EUNEP)
Authors: Y. Meissner, A. Strangfeld, N. Costedoat-Chalumeau, F. Förger, A. Molto, M. Wallenius, R. Fischer-Betz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> There is a high unmet need of robust data on the outcomes of pregnancies and drug safety in various inflammatory rheumatic diseases (IRD). The aims of the European Network of Pregnancy Registers in Rheumatology (EuNeP) are to bring together experts who run pregnancy registers, to define a core data set and to perform concerted data analyses. <h3>Objectives</h3> To describe data items collected in existing multicentre European pregnancy registers in rheumatology. <h3>Methods</h3> A comprehensive survey on details of the registers was performed encompassing patient enrolment, inclusion criteria, demographics, disease specific and general outcomes, medical treatment, course and outcome of pregnancy and outcomes of the child. Free text answers were possible for all questions. Questionnaires were sent to the principle investigator(s) of the participating studies. The completed questionnaires were reviewed, and responses were evaluated descriptively. Only data items collected during pregnancy are shown. <h3>Results</h3> The following registers are involved in the collaboration: EGR2 (France), RePreg (Switzerland), REVNATUS (Norway) and Rhekiss (Germany). All registers collect data prospectively and nationwide. Patients can be included before pregnancy (child wish) or during pregnancy in all registers, and in RePreg also up to week 8 postpartal. Enrolment during pregnancy is possible up to gestation week 12 or thereafter in some specific cases (EGR2), week 20 (Rhekiss) or during complete pregnancy (RePreg and REVNATUS). All registers capture data via IT-based systems, REVNATUS documented on paper until 2016. During pregnancy, data is reported once every trimester by physicians and patients. Current figures, baseline characteristics and included IRD are presented in the table. Most of the data items that are independent of the underlying IRD are collected by all registers (figure 1). However, there are differences in the way data is collected and in the level of details. <h3>Conclusions</h3> Although the registers in this collaboration have similar designs, we found considerable differences in data items collected. In particular, the level of details of documented data and the information on disease-specific characteristics varied. Harmonisation of data collected in pregnancy registers would facilitate collaborative analysis. <h3>Acknowledgements</h3> This work was supported by a research grant from FOREUM Foundation for Research in Rheumatology. <h3>Disclosure of Interest</h3> Y. Meissner: None declared, A. Strangfeld: None declared, N. Costedoat-Chalumeau: None declared, F. Förger Grant/research support from: UCB Pharma, Speakers bureau: Mepha, Roche, UCB Pharma, A. Molto: None declared, M. Wallenius: None declared, R. Fischer-Betz: None declared
Anti‐Inflammatory Nanotherapeutics: Peptide–Gold Nanoparticle Hybrids as Promising Anti‐Inflammatory Nanotherapeutics for Acute Lung Injury: In Vivo Efficacy, Biodistribution, and Clearance (Adv. Healthcare Mater. 19/2018)
Authors: Ye Xiong, Wei Gao, Fan Xia, Yi Sun, Liya Sun, Ling Wang, Suqin Ben, Stuart E. Turvey, Hong Yang, Qiang Li
Journal: Advanced Healthcare Materials (2018)

In article 1800510, Hong Yang, Qiang Li, and co-workers, report a unique class of peptide-decorated gold nanoparticles that can target pulmonary phagocytic immune cells, to reduce lung inflammation through inhibiting TLR4 signaling, decreasing the neutrophil infiltration, and increasing the number of regulatory T cells. The nanoparticles can then be rapidly and effectively excreted with minimum accumulation in the liver and spleen.
Decreased Admission Rate From the Emergency Department With Increased Emergency Department Visits—The Good and the Bad
Authors: Mitchell H. Katz
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Tumor hypoxia as a mechanism of resistance to bevacizumab in a murine model.
Authors: Linda Heijmen, Otto C. Boerman, Cornelis J. A. Punt, E. Ter Voert, Wim J.G. Oyen, Jan Bussink, Fred C.G.J. Sweep, Peter Laverman, Paul Span, Lioe-Fee de Geus- Oei, Arend Heerschap, Hanneke W.M. Van Laarhoven
Journal: Journal of Clinical Oncology (2012)

e13111 Background: Despite the promise of preclinical and early phase clinical studies, the efficacy of bevacizumab in solid tumors is more limited than expected. One of the presumed reasons is the induction of tumor hypoxia by the anti-angiogenic effects of bevacizumab, leading to therapy resistance. The aim of this study was to assess the effect of bevacizumab on tumor hypoxia in vivo in a colorectal cancer model, using functional imaging techniques. Methods: Nude mice with s.c. LS174T colon carcinoma xenografts (0.05 - 0.3 cm 3 ) were treated with bevacizumab (5 mg/kg; 2/wk, i.p.) or saline as a control. To assess tumor hypoxia in vivo 18 F-MISO-PET microPET or T2*-MRI images were acquired of separate groups of mice (n=5) before treatment and at day 2, 6 and 10 days after start of treatment. Tumors were harvested directly after imaging to microscopically assess the hypoxic fraction (pimonidazole staining) and vascular density (9F1 staining). Results: Linear regression analyses showed that FMISO uptake increased significantly more over time in the control group than in the bevacizumab group (beta -0.44, p=0.02), indicating that bevacizumab reduced the inherent increase in tumor hypoxia over time. T2* time increased significantly less in the bevacizumab group (beta -0.45, p=0.01), indicating a higher deoxyhemoglobine concentration, which might indicate a higher perfusion of the tumor and thus less hypoxia. The hypoxic fraction did not change over time and no difference was observed between the tumors in the treated and the control group. Vessel density significantly decreased over time in the bevacizumab group (beta -0.25, p=0.05), while the hypoxic fraction remained unchanged in the control group. Conclusions: The bevacizumab-induced changes in the tumor were most prominent at 10 days after treatment initiation, implying a build-up effect of repeated bevacizumab administration. The treatment induced changes could be detected with both T2*-MRI as well as with FMISO microPET. Bevacizumab did not induce tumor hypoxia, despite the observed decrease in vascular density. Therefore, induction of tumor hypoxia as a resistance mechanism to bevacizumab treatment seems unlikely.
Time for Clinicians to Embrace Their Inner Bayesian?
Authors: Roger J. Lewis, Derek C. Angus
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Magnetic Resonance Imaging–Based Prediction of Prostate Cancer Risk—Reply
Authors: Sherif Mehralivand, Joanna Shih, Baris Turkbey
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract MP053: Dietary Trimethylamine Intake and Cardiovascular Mortality Among Urban Chinese Adults
Authors: Danxia Yu, Gong Yang, Yong-Bing Xiang, Honglan Li, Yu-Tang Gao, Wei Zheng, Xiao-Ou Shu
Journal: Circulation (2017)

Background: Trimethylamine (TMA)-containing nutrients (choline, betaine and carnitine) are dietary precursors of a gut microbial-derived metabolite, trimethylamine-N-oxide (TMAO). Studies have suggested that elevated TMAO contributes to atherosclerosis and increased mortality in cardiovascular disease (CVD) patients. However, epidemiological evidence remains limited regarding whether high TMA intake may increase CVD mortality. No population-based study has evaluated animal vs. plant food-derived TMA in relation to CVD. Objective: We examined dietary TMA, from animal-source foods (e.g., eggs, red meat and fish) and/or from plant foods (e.g., soy foods, legumes and vegetables), in association with total CVD mortality and mortality from coronary heart disease (CHD) and ischemic and hemorrhagic stroke. We also evaluated whether the associations were modified by food sources of TMA and by major CVD risk factors. Methods: Included were 73216 women and 61190 men from two prospective cohort studies of Chinese adults. They were 40-74 years of age, free of cancer and with a plausible energy intake at baseline. Usual diets were assessed using food-frequency questionnaires. Dietary TMA intake was calculated using the USDA database. Vital status and cause of death were obtained via linkages with the vital statistics registry. Cox model was used to estimate HRs and 95% CIs. Results: During a mean follow-up of 12.5 years, we documented 3740 CVD deaths. After adjusting for potential confounders, including sociodemographics, lifestyle, disease history, and other dietary risk factors, high TMA intake was associated with increased mortality from total CVD and CHD–HR (95% CI) in the highest vs. lowest quintile of TMA intake was 1.33 (1.15, 1.53) for CVD mortality and 1.60 (1.25, 2.06) for CHD mortality; both p-trend=0.0001. A positive trend of association was also observed for ischemic stroke mortality (HR [95% CI] =1.31 [0.99, 1.74]), but not for hemorrhagic stroke mortality. With mutual adjustment, animal- and plant-sourced TMA showed similar magnitude of positive associations with CVD and CHD mortality–HR (95% CI) in the highest vs. lowest quintile was 1.13 (0.99, 1.29) for animal-TMA and 1.19 (1.07, 1.33) for plant-TMA related to CVD mortality, and 1.33 (1.05, 1.67) for animal-TMA and 1.29 (1.07, 1.57) for plant-TMA related to CHD mortality. The TMA-CVD mortality association seemed more evident in men than in women and among adults with higher socioeconomic status, higher waist-hip ratios, higher refined carbohydrate intakes, or diabetes, although no interactions were statistically significant. Conclusion: Our study suggests that high TMA intake, from either animal or plant food sources, is associated with increased mortality from atherosclerotic CVD among urban Chinese adults. Potential mechanism involving gut microbial production of TMAO needs to be investigated in future studies.
Abstract 15010: Women Have Better Long-Term Prognosis After Myocardial Infarction Regardless of Less Aggressive Treatment - Results From a Nationwide Cohort in Finland
Authors: Ville Kytö, Tuire Prami, Houssem Khanfir, Anna Deleskog, Pål Hasvold, Eeva Reissell, Juhani Airaksinen
Journal: Circulation (2016)

Introduction: The aim of this study was to describe sex differences in prognosis and risk of subsequent cardiovascular events after myocardial infarction (MI), with a focus on patients surviving more than one year without subsequent MI or stroke. Methods: This observational study linking patient-level data from different nationwide registers included patients discharged from hospitals after MI in Finland in 2009-2012. Patients ≥ 18 years of age surviving 7 days after the index MI were included. Primary end points were re-infarction, stroke, cardiovascular mortality and overall mortality. The patients were followed until the end of 2013. Results: The study cohort consisted of 35,238 MI patients (60% men), of whom 67% were hospitalized due to NSTEMI. PCI was performed in 36% of all patients (in 46% of patients < 80 years old and in 16% of patients ≥ 80 years old). When stratifying by sex, 43% of the men and 25% of the women underwent PCI. After adjustments, women were significantly less likely to undergo PC...
Deep echocardiography: data-efficient supervised and semi-supervised deep learning towards automated diagnosis of cardiac disease
Authors: Ali Madani, Jia Rui Ong, Anshul Tibrewal, Mohammad R. K. Mofrad
Journal: npj Digital Medicine (2018)

Deep learning and computer vision algorithms can deliver highly accurate and automated interpretation of medical imaging to augment and assist clinicians. However, medical imaging presents uniquely pertinent obstacles such as a lack of accessible data or a high-cost of annotation. To address this, we developed data-efficient deep learning classifiers for prediction tasks in cardiology. Using pipeline supervised models to focus relevant structures, we achieve an accuracy of 94.4% for 15-view still-image echocardiographic view classification and 91.2% accuracy for binary left ventricular hypertrophy classification. We then develop semi-supervised generative adversarial network models that can learn from both labeled and unlabeled data in a generalizable fashion. We achieve greater than 80% accuracy in view classification with only 4% of labeled data used in solely supervised techniques and achieve 92.3% accuracy for left ventricular hypertrophy classification. In exploring trade-offs between model type, resolution, data resources, and performance, we present a comprehensive analysis and improvements of efficient deep learning solutions for medical imaging assessment especially in cardiology.
Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis
Authors: Natasha Szuber, Terra L. Lasho, Christy Finke, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Journal: Leukemia (2018)
Less than half of women are diagnosed with ovarian cancer within a month of seeing a doctor, finds survey
Authors: Susan Mayor
Journal: BMJ (2018)

Less than half of women with symptoms that are common in ovarian cancer are diagnosed within one month of first seeing a doctor, a large global survey of women with the disease1 has found. Results also revealed low levels of awareness of the cancer among women and delays in seeking medical help.

“This study, for the first time, provides powerful evidence of the challenges faced by women diagnosed with ovarian cancer across the world, and sets an agenda for global change,” said Anwen Jones, chief executive officer of Target Ovarian Cancer in the UK and co-chair of the study, which was funded by …
Matching-adjusted indirect comparison of benralizumab <i>versus</i> interleukin-5 inhibitors for the treatment of severe asthma: a systematic review
Authors: Arnaud Bourdin, Don Husereau, Nicolas Molinari, Sarowar Golam, Mohd Kashif Siddiqui, Leandro Lindner, Xiao Xu
Journal: European Respiratory Journal (2018)

Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody that directly depletes eosinophils. Its relative efficacy versus other IL-5-targeted treatments for patients with severe, uncontrolled asthma is not yet fully characterised. We performed a matching-adjusted indirect comparison (MAIC) of benralizumab versus mepolizumab and reslizumab. Trials were selected through systematic review and evaluation of trial methods. Benralizumab patient-level data were weighted to match treatment-effect-modifying patient characteristics of comparator trials before indirect efficacy comparisons. After matching adjustment, benralizumab and mepolizumab reduced exacerbations versus placebo by 52% and 49%, respectively (rate ratio [RR] 0.94, 95% CI 0.78–1.13; n=1524) and reduced the rate of exacerbations requiring hospitalisation/emergency department visit by 52% and 52%, respectively (RR 1.00, 95% CI 0.57–1.75; n=1524). Benralizumab and mepolizumab similarly improved pre-bronchodilator forced expiratory volume in 1 s at 32 weeks (difference 0.03 L, 95% CI −0.06–0.12; n=1443). Benralizumab and reslizumab patient populations were too dissimilar to generate a sufficient effective sample size to produce a reliable estimate for MAIC. MAIC is a robust way to indirectly compare treatment efficacies from trials with heterogeneous patient populations. When baseline patient characteristics were matched across asthma trials, benralizumab and mepolizumab yielded similar efficacy.
Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/AKT pathway
Authors: X. Fu, M. Liu, S. Qu, J. Ma, Y. Zhang, T. Shi, H. Wen, Y. Yang, S. Wang, J. Wang, K. Nan, Y. Yao, T. Tian
Journal: Annals of Oncology (2018)
Cardiovascular Disease Among Women Who Gave Birth to an Infant With a Major Congenital Anomaly
Authors: Eyal Cohen, Erzsébet Horváth-Puhó, Joel G. Ray, Lars Pedersen, Vera Ehrenstein, Nancy Adler, Simone Vigod, Arnold Milstein, Henrik Toft Sørensen
Journal: JAMA Network Open (2018)

<h3>Importance</h3> Having a child with a major birth defect can be a life-changing and stressful event that may be associated with higher cardiovascular disease (CVD) risk, yet the long-term burden of CVD for the child's mother is unknown. <h3>Objective</h3> To assess whether mothers of an infant born with a major congenital anomaly are at higher risk of CVD compared with a comparison cohort. <h3>Design, Setting, and Participants</h3> A population-based cohort study using individual-level linked registry data in Denmark included 42 943 women who gave birth to an infant with a major congenital anomaly between January 1, 1979, and December 31, 2013; and follow-up was conducted until 2015. A comparison group, comprising 428 401 randomly selected women, was 10:1 matched to each affected mother by maternal age, parity, and her infant's year of birth. Data analyses were performed between November 1, 2017, and February 28, 2018. <h3>Exposures</h3> Live birth of an infant with a major congenital anomaly. <h3>Main Outcomes and Measures</h3> The primary outcome was a CVD composite outcome of acute myocardial infarction, coronary revascularization, or stroke. Secondary outcomes included individual components of the CVD composite and other cardiovascular outcomes, including unstable angina, congestive heart failure, atrial fibrillation, peripheral artery disease, ischemic heart disease, and aortic aneurysm. Cox proportional hazards regression analyses generated hazard ratios (HRs), adjusted for maternal demographic, socioeconomic, and chronic health indicators. <h3>Results</h3> Median maternal age at baseline was 28.8 years (interquartile range, 25.3-32.5 years). After a median follow-up of 19.5 years (interquartile range, 9.9-27.6 years), 914 women whose infant had a major congenital anomaly experienced a CVD event (1.21 per 1000 person-years; 95% CI, 1.13-1.28 per 1000 person-years) vs 7516 women in the comparison group (0.99 per 1000 person-years; 95% CI, 0.97-1.01 per 1000 person-years), corresponding to an unadjusted HR of 1.23 (95% CI, 1.15-1.32), and an adjusted HR (aHR) of 1.15 (95% CI, 1.07-1.23). Women who gave birth to an infant with multiorgan anomalies had an even higher aHR (1.37; 95% CI, 1.08-1.72). Mothers of infants with a major anomaly also had an increased aHR of the individual components of the composite outcome and the other cardiovascular outcomes. <h3>Conclusions and Relevance</h3> Women whose child had a major congenital anomaly experienced a 15% to 37% higher risk of premature cardiovascular disease. These women may benefit from targeted interventions aimed at improving their cardiovascular health.
GW29-e1406 Prognostic Value of Right Ventricular Strain in Patients with Heart Failure and Preserved Ejection Fraction: A Three-Dimensional Speckle Tracking Echocardiography Study
Authors: Yuman Li, Yuanli Meng, Jing Wang, Qing Lv, Mingxing Xie
Journal: Journal of the American College of Cardiology (2018)
Changes in long-term prognosis with increasing postnatal survival and the occurrence of postnatal morbidities in extremely preterm infants offered intensive care: a prospective observational study
Authors: Jeanie L Y Cheong, Katherine J Lee, Rosemarie A Boland, Alicia J Spittle, Gillian F Opie, Alice C Burnett, Leah M Hickey, Gehan Roberts, Peter J Anderson, Lex W Doyle, Jeanie L Y Cheong, Carolyn Anderson, Peter J Anderson, Merilyn Bear, Rosemarie A Boland, Alice C Burnett, Catherine Callanan, Elizabeth Carse, Margaret P Charlton, Janet Courtot, Noni Davis, Lex W Doyle, Julianne Duff, Anjali Haikerwal, Leah Hickey, Esther Hutchinson, Marie Hayes, Elaine Kelly, Katherine J Lee, Marion McDonald, Emma McInnes, Bronwyn Novella, Gillian F Opie, Gehan Roberts, Katherine Scott, Anne-Marie Turner, Amanda Williamson
Journal: The Lancet Child & Adolescent Health (2018)
Abstract 16305: A Comparison of Patients Implanted With Cardiac Resynchronization Therapy Pacemaker versus Cardiac Resynchronization Therapy Defibrillator -Results From the European Society of Cardiology Survey II With 11,088 Patients
Authors: Camilla Normand
Journal: Circulation (2017)

Introduction: Cardiac Resynchronization Therapy (CRT) reduces morbidity and mortality in selected patients with heart failure and electrical dyssynchrony and therefore receives strong recommendatio...